Aug. 30, 2000--Northwest Biotherapeutics, Inc. announced today that it has executed an exclusive worldwide agreement with Cytogen Corporation clarifying Northwest Biotherapeutics' right to make, have made, use, and sublicense Prostate Specific Membrane Antigen ("PSMA"), a protein highly associated with prostate, and prostate cancer cells, for ex vivo prostate cancer immunotherapy.
The terms of the agreement were not disclosed.
"We are very pleased with the execution of this agreement," commented Daniel Wilds, President and CEO of Northwest Biotherapeutics. "It serves to solidify Northwest Biotherapeutics' position as a leader in the development of immunotherapy for the treatment of prostate cancer."
Mr. Wilds also noted that Northwest Biotherapeutics is sponsoring a 60 patient clinical trial at M.D. Anderson Cancer Center in Houston and the University of California, Los Angeles (UCLA) to evaluate the safety and efficacy of using recombinant PSMA with its proprietary dendritic cell immunotherapy, DCVaxTM, for late stage prostate cancer patients with no remaining treatment options.
The American Cancer Society estimates that approximately 32,000 U.S. men will die from late stage prostate cancer this year.
Northwest Biotherapeutics, Inc. is a Seattle, Washington based, privately held company founded in 1996 to develop and commercialize products and services to improve care for prostate and other cancer patients. In addition to prostate cancer, Northwest Biotherapeutics is developing its proprietary dendritic cell-based immunotherapy platform for application to a number of life-threatening forms of cancer.
For additional information on Northwest Biotherapeutics, visit the Company's web site at www.nwbio.com.
Jim |
